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Abstract 
Background: Placental like alkaline phosphate (PLAP), an oncofetal antigen, is highly expressed in germ cell, cervical, 
ovarian and several other tumour types but minimally in normal tissues. The expression of a PLAP promoter based 
transcriptional unit following antigen mediated cell specific delivery is a possible approach for tumour targeting.
Methods: PLAP promoter alone or in combination with NFκB DNA response elements was used for expressing 
shRNA targeting the long control region (LCR) of human papillomavirus (HPV)-16 oncogenes E6 and E7 via transcrip-
tional gene silencing in PLAP expressing cervical cancer cell lines, SiHa and CaSki. This was packaged in a Sendai virus 
envelope incorporating a single chain variable fragment antibody (scFv) for antibody mediated targeting. Specificity 
and efficacy of the shRNA was assessed by studying the heterochromatization, down regulation of the HPV-16 E6/E7 
genes and subsequent effects on their targets and cell growth properties.
Results: Reduction of HPV-16 E6 and E7 expression by TGS led to the activation of the previously suppressed target 
genes of p53 (PUMA and NOXA) and Rb (cyclins A2 and E). Cell death was seen only in PLAP expressing HPV-16 
infected SiHa and CaSki cells but not in the HPV-18 integrated HeLa and non-PLAP CHO cells. There was reduction 
in the enhancer associated transcripts of the long control region (LCR) of HPV-16 E6/E7 genes. Also, an increase in 
the enrichment of dimethylated histone three lysine nine (H3K9Me2) and trimethylated histone three lysine twenty-
seven (H3K27Me3) was observed by ChIP assay, which decreased upon trichostatin A treatment, indicating a possible 
mechanism for the heterochromatization of the target LCR region.
Conclusion: A combination of novel PLAP promoter and antibody based specificities has the potential for being 
developed as a possible therapeutic strategy for PLAP positive neoplasia.
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Background
Tumour targeting is fraught with complexities result-
ing from the difficulties in identifying specific attributes 
of neoplasia. Effective tumour management requires 
modalities which specifically suppress neoplastic cell 
programming. Tumour specific antigens like HER2/neu 
and CD20 have been shown to be useful for combating 
tumours [1–3]. In some cases such antigens have been 
targeted for specific delivery by antibody and particu-
late delivery approaches [4–6]. Neoplasia specific tran-
scription is another avenue by which the response in 
tumours may be heightened. Tumour specific promoters 
like α-fetoprotein (AFP) to target hepatocellular carci-
noma (HCC) [7], prostate-specific antigen (PSA) to tar-
get prostate cancer [8] and others [9] have been used to 
suppress tumour growth. We reasoned that combining 
an antibody based targeting modality with a construct 
based on antigen’s own promoter would provide a novel 
way for increasing tumour specificity and efficacy. Our 
laboratory has been working on distinct but immunologi-
cally identical oncofetal isozymes of alkaline phosphates 
(APs); the placental alkaline phosphate (PAP) and placen-
tal like alkaline phosphate (PLAP). In this study, we have 
attempted to combine a recombinant antibody based 
Sendai virosomal delivery system with a PLAP promoter 
driven shRNA for TGS.
PLAP is most frequently expressed in germ cell 
tumours [10], cervical cancer [11], ovarian cancer [12], 
but not generally in normal tissue with only a negligible 
degree of expression in normal cervix [13]. The ectopic 
expression of PLAP in malignantly transformed colon 
cancer cell lines has been studied by Deng and co-work-
ers [14] who have extensively analysed PLAP promoter 
activity in the cells. Based on the activation of the PLAP 
promoter in these transformed cells, we reasoned that is 
could be used to provide targeted specificity to those cells 
where this oncofetal antigen is expressed.
A common causative factor in the etiology of cervical 
cancer is HPV [15]. The aggressiveness of cervical can-
cer is dependent on the expression of viral onco-proteins 
E6 and E7 [16, 17]. Transcription of both E6 and E7 in 
HPV-16 is governed by long control region (LCR) com-
prising of strong distal enhancer and weak proximal pro-
moter p97 [18]. Therefore, targeting this region by TGS 
would simultaneously down regulate both E6 and E7. 
Conventional post-transcriptional gene silencing (PTGS) 
approach requires separate siRNAs against E6 and E7 
transcripts; this could saturate RNAi machinery [19]. 
Additionally, the effects of TGS, unlike PTGS, are long 
lasting and genetically transmissible to the daughter cells 
[20]. Polymerase (pol) III promoters, due to their consti-
tutive expression, fail to differentiate between normal and 
neoplastic cells; hence are not suitable for therapeutic 
shRNA applications [21]. To overcome this limitation, we 
used tumour specific PLAP promoter for expression of 
shRNA targeting one of the nuclear factor (NF)-1 bind-
ing site in the enhancer region of HPV-16. Further, to 
augment promoter mediated shRNA expression, without 
compromising tissue specificity, NFκB response elements 
and PLAP promoter were used in tandem.
Delivery of siRNA/shRNA, specifically to the cancer 
cell, is often limited due to lack of suitable approaches 
[22]. PLAP is a cancer cell membrane antigen [23] and 
can be manipulated for the development of tumour 
directed vehicular systems. Previously, we have been 
successful in the development of a single chain variable 
fragment antibody (scFv) based chimeric F-virosomal 
delivery system based on PAP, which is antigenically 
indistinguishable from PLAP [24]. In this study, TGS 
constructs delivered by such recombinant particulate 
virosomal delivery system unloaded the cargo specifi-
cally in PLAP expressing cells and produced knockdown 
effects only in HPV-16 infected cells SiHa and CaSki. In 
addition, such shRNA system induced heterochroma-
tization of the target region without affecting the meth-
ylation pattern of CpG islands. Our results show that 
engineered immuno-virosomes and TGS inducing con-
structs provide dual specificity to tumour targeting in 
terms of delivery and cellular expression, hence, could be 
foreseen as a potential gene therapy tool.
Methods
Cell culture
PLAP positive cervical cancer (HeLa, SiHa and CaSki), 
PLAP negative hepatocellular carcinoma (HepG2) and 
non-PLAP, non-human Chinese hamster ovary (CHO) 
cell lines were used in this study. HeLa, HepG2 and CHO 
were obtained from American Type Culture Collec-
tion (ATCC) while SiHa and CaSki were obtained from 
National Centre for Cell Science (NCCS), Pune. Cells 
were cultured as per ATCC recommendations.
Construction of PLAP promoter/enhancer based reporter 
systems
Region of the PLAP promoter previously shown to drive 
tissue specific expression was cloned upstream to the pGl3 
Basic luciferase plasmid (Promega, USA). In order to gen-
erate a hybrid clone of the above with NFκB enhancer, ten 
nucleotides of NFκB enhancer sequence (10 ×  4 copies) 
were cloned upstream to the PLAP promoter. Details of 
the cloning are provided in the Additional file 1. NFκBEn–
Pr+24-luc and PLAPPr+24-luc generated constructs 
were authenticated by restriction endonuclease digestion 
(Additional file 1: Figure S1A) and DNA sequencing. The 
sequence of PLAP promoter and enhancer elements are 
given in Additional file 2: Figure S2A.
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Generation of TGS inducing system: PLAP promoter/
enhancer + 2 HPV‑16 E6/E7 shRNA
shRNA targeting NF-1 binding site on the enhancer 
region of HPV-16 LCR was designed using online siRNA 
wizard (http://www.sirnawizard.com/construct.php). 
100 pico moles of sense and antisense oligonucleotides 
(with pre-added sticky ends; 5′BamHI and 3′HindIII) 
were annealed as described by Zakaria et al. [25]. Details 
of the directional cloning strategy so that the shRNA was 
located downstream to the (1) PLAP promoter alone 
or (2) NFκB–PLAP promoter are described in Addi-
tional file  1. All the clones were confirmed by restric-
tion digestion and authenticated by DNA sequencing 
before being used for transfection (Additional file 1: Fig-
ure S1B, C). This generated the constructs—NFκBEn–
Pr+2-HPV-16–E6/E7, PLAPPr+2-HPV-16–E6/E7, and 
their appropriate scrambled controls NFκBEn–Pr+2-
HPV-16–E6/E7 Scr, PLAPPr+2-HPV-16–E6/E7 Scr. 
shRNA under CMV promoter, CMVPr–HPV-16–E6/E7, 
served as positive control.
Transfection
Cells were plated at 105 cells per well in a six-well plate, 
3  ×  105 cells per 25  cm2 flask or 106 cells per 75  cm2 
flask (Corning, USA). Twenty-four hours later, they 
were transfected with different PLAP promoter based 
reporter or shRNA constructs using Lipofectamine™ 
2000 (Invitrogen, USA). For preparing transfectants, 
required amount of plasmid DNA was mixed with opti 
MEM media in a microfuge tube and separately Lipo-
fectamine™ 2000 was mixed with opti MEM keeping the 
final volume of each tube to 50 µl. Both the tubes were 
incubated for about 30  min followed by transferring 
the contents of DNA + opti MEM to the tube contain-
ing Lipofectamine + opti MEM. The tube was incubated 
again for 30 min. Meanwhile, cells were washed with opti 
MEM media and 900 µl of opti MEM was added to each 
well of a 6-well plate. The contents of the tube were then 
added into each well. Four hours later, DMEM containing 
2× serum was added and the cells were incubated. The 
dose of Lipofectamine™ 2000 used per/µg of plasmid was 
2.5 µl. The dose of the shRNA used was 1.8 µg/well of a 
6-well plate.
Dual luciferase assay
All the three luciferase constructs: PLAPPr+24-luc, 
NFκBEn–Pr+24-luc and SV40-luc were transfected in a 
battery of cell lines. The passive lysis buffer, LAR II solu-
tion and Stop & Glo reagent were prepared as advised 
by the manufacturer (Promega, USA). Cells were plated 
onto 6-well plate and when 70% confluent, media was 
removed and cells were rinsed with PBS. 500 µl of passive 
lysis buffer was added into each well. Plate was kept on 
a rocker/shaker for 15  min to completely disrupt the 
cells. 20  µl of the resulting cell lysate was mixed with 
100  µl of LAR II solution in a tube and luminescence 
was recorded. This was followed by addition of stop and 
glo solution (100 µl) and again the second readings were 
obtained. The firefly luciferase activity was normalized 
against Renilla luciferase activity and expressed relative 
to promoter-less pGl3-Basic control vector.
Real‑time PCR
NFκBEn–Pr+2-HPV-16–E6/E7, PLAPPr+2-HPV-16–
E6/E7, CMVPr–HPV-16–E6/E7 and their appropriate 
scrambled controls were transfected in cell lines by fol-
lowing transfection protocol as described above. Tri-
zol (Sigma-Aldrich) reagent was used for isolation of 
RNA at requisite time points. In order to remove DNA 
contamination from the extracted RNA, it was treated 
with DNase (MBI Fermentas) and quantified by Nan-
oDrop ND-1000 (Thermo Fisher Scientific). About 500–
1,000 ng of RNA was used for preparing cDNA by using 
random decamer as primers. Moloney murine leukemia 
virus reverse transcriptase (MBI Fermentas) was used for 
preparing cDNA. Real time PCR was done on a Rotor-
Gene 6000 real-time PCR machine (Corbett Research, 
Australia). For quantitation of target genes, we used three 
reference genes as an internal control—18S, GAPDH and 
β-actin. Relative Expression Software Tool (REST) was 
used for relative quantitation. The list of primers used in 
all experiments is given in Additional file 2.
Cell proliferation assay
Overnight-cultured cells, 2  ×  104 per well, in 24-well 
plates, were transfected with PLAP promoter/enhancer 
driven shRNA constructs or their respective scrambled 
controls. Cell proliferation was estimated on the 6th day. 
On the 6th day, 10  µl of MTT reagent (Sigma Aldrich) 
was added to each well and the plate was incubated for 
2  h. 100  µl of solubilisation buffer was added and the 
plate was again incubated in the dark for 2  h. 100  µl of 
the solution from each well was transferred onto 96-well 
plate and absorbance was measured at 570 nm.
Apoptosis study
105 cells were seeded in 25 cm2 cell culture flask (Corn-
ing, USA) followed by transfection with various shRNA 
constructs. On the 6th day, 70% ice-cold ethanol was 
utilized for fixing the cells. Propidium Iodide (PI; Sigma-
Aldrich, Germany) was used for staining and Flow 
cytometer (BD Biosciences, USA) helped to capture the 
fluorescence. Cell cycle analysis was done using WinMDI 
software (http://winmdi.software.informer.com/2.8/)
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Western blotting
On the 6th day post transfection/immuno-virosomal 
delivery of shRNA constructs, cells were washed with 
PBS followed by lysis using triple lysis buffer [50 mmol/L 
Tris–Cl (pH 7.4), 150  mmol/L NaCl, 0.02% sodium 
azide, 0.1% SDS, 1% NP40, and 0.5% sodium deoxycho-
late]. Supernatants were extracted by centrifuging the 
lysates for 10 min. 5–12% SDS–PAGE gels were used for 
resolving equal quantities of protein followed by electro 
transfer on to nitrocellulose membranes. Blocking was 
done at room temperature using 4% BSA. Immunoblot-
ting antibodies used were anti-actin (sc-8432) and anti-
p53 (sc-126; Santa Cruz Biotechnology). Detection was 
done by ECL detection system (Applied Biosystems, 
USA) by using horseradish peroxidase labelled secondary 
antibodies.
Preparation of chimeric scFv targeted fusion (F) Sendai 
virosomes and loading of shRNA constructs
This is fully described by Kumar et al. [24]. In brief, the 
following process went into the generation of the scFv 
targeted Sendai virosome. (1) The scFv antibody that had 
been demonstrated to bind specifically to PAP isozyme 
was fused in frame with a portion of the Sendai viro-
some’s F protein containing a segment of its membrane 
spanning region. (2) The virosome was then reconstituted 
to include both the scFv linked F protein and the wild 
type F protein in a ratio of 1:5. (3) The DNA constructs 
were incorporated as required within the virosome dur-
ing the process of reconstitution of the virosome com-
ponents. (4) The appropriate cells were exposed to the 
scFv targeted virosomes loaded with DNA constructs as 
described by Kumar et al. [24] and Zakaria et al. [25]. A 
schematic diagram is given in Additional file 3. In brief, 
targeting by scFv results in the juxtaposition of the viro-
some to the PLAP expressing cell. The membrane of the 
virosome and the cell then fuse as a result of the wild type 
F protein, which then results in direct cytoplasmic deliv-
ery of the packaged DNA constructs.
Live cell fusion: kinetics of chimeric scFv‑F‑virosome fusion
1 mg/ml of Triton X-100 containing dialyzed and reduced 
Sendai virus envelope was mixed with 10 µl of ethanolic 
solution of octadecyl Rhodamine (R18) (1  mg/ml). This 
was vortexed and incubated in dark at room temperature 
for 30  min. Ultra-centrifugation, at 1,00,000g, was done 
to remove unbound R18 for 1  h at 4°C. Cells (1 ×  106) 
were incubated with 2 μg of R18 labelled scFv virosomes 
for 1 h at 4°C and then centrifuged at 2,000 rpm for 5 min 
to remove unbound virosomes. The pellet was then sus-
pended in 100 µl of cold 10 mM PBS. 50 µl of the labeled 
scFv-cell complex suspension was placed in a cuvette 
containing 3 ml of PBS with 1.5 mM Ca2+ (pre-warmed 
to 37°C). Kinetics of fusion was recorded online by a 
spectrofluorimeter (Horiba, USA). This is based on 
dequenching of a fluorescent dye R18 after fusion, with 
extent of dequenching being directly proportional to the 
virosome cell fusion (Additional file 3).
CpG methylation study
DNA was isolated post virosomal delivery of NFκBEn–
Pr+2-HPV-16–E6/E7 or its scrambled control on the 6th 
day using Gen Elute Mammalian genomic DNA Mini-
prep Kit (Sigma-Aldrich, Germany). 500  ng of genomic 
DNA was bisulphite treated using EpiTect Bisulphite Kit 
(Qiagen, Germany). Bisulphite primers were designed 
from http://bisearch.enzim.hu/. Primers were M13-
tagged for sequencing of PCR products.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay for H3K9Me2 and H3K27Me3 was done 
using EZ ChIP kit (Millipore, USA) as per manufacturer’s 
protocol. Immunoprecipitated DNA was amplified using 
primers specific for target region of HPV-16 LCR. Immu-
noprecipitation percentage was calculated as described 
earlier [26]. Cells were pre-treated with Trichostatin A 
(TSA; Sigma-Aldrich, Germany; 300  nM) for 48  h fol-
lowed by virosomal delivery of the NFκBEn–Pr+2-
HPV-16–E6/E7 or its scrambled control.
Caspase 3/7 assay
Caspase-3/7 activity was determined post virosomal 
delivery of NFκBEn–Pr+2-HPV-16–E6/E7 or NFκBEn–
Pr+2-HPV-16–E6/E7 Scr using caspase-3/7 assay kit 
(Promega, USA).
Statistical analysis
All experiments like dual luciferase assay, cell prolif-
eration assay and RT-PCR were performed in triplicates 
and repeated thrice. Western blotting, fluorescence 
dequenching assay, Flow cytometric analysis, Bisulfite 
PCR, ChIP assay and capase 3/7 assay were repeated at 
least twice. Student’s t test was utilized to calculate the 
significance in all experiments and p < 0.05 was consid-
ered significant whereas p  <  0.001 as highly significant. 
The data are shown as mean ± SD.
Results
The transcriptional efficiency and specificity of PLAP 
promoter and enhancer systems
Generated luciferase constructs PLAPPr+24-luc; 
NFκBEn–Pr+24-luc demonstrated selective transcrip-
tional activity only in the PLAP positive cervical cancer 
cell lines (HeLa, SiHa and CaSki). The transcriptional 
activity of NFκBEn–Pr+24-luc was comparable to that 
of strong SV40 promoter (SV40-luc; Fig. 1a–c; p > 0.05). 


















































































































































































































































Fig. 1 Cervical cancer specific expression of PLAP promoter/enhancer system. a–c 48 h after transfection, luciferase activity by enhancer/promoter 
system was observed only in PLAP positive cervical cancer cell lines HeLa, CaSki, and SiHa. It was highest in case of NFκBEn–Pr+24-luc. SV40-luc 
showed nonspecific tissue expression. d and e No, luciferase activity was observed through PLAP promoter/enhancer systems in non-PLAP HepG2 
and CHO cells. Luciferase activity observed by NFκBEn–Pr+24-luc was significantly higher when compared to that by PLAPPr+24-luc (p = 0.022).
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However, SV40-luc also demonstrated high transcrip-
tional activity even in PLAP negative cell lines HepG2 
and CHO indicating its non-specific nature (Fig.  1d, 
e). Also, greater degree of luciferase expression was 
observed by NFκBEn–Pr+24-luc over PLAPPr+24-luc 
(p = 0.022).
Reduction in E6 and E7 expression is HPV‑16 specific
NFκBEn–Pr+2-HPV-16–E6/E7 or NFκBEn–Pr+2-
HPV-16–E6/E7 Scr were transfected in SiHa cells and 
fall in expression of HPV-16 E6 and E7 was evaluated 
consecutively for 6  days This decrease was signifi-
cant at all-time points (p  <  0.05) and was maximum 
on the 5th day (Fig.  2a). Slight apparent increase 
on the 6th day compared to the 5th day was insig-
nificant (p  =  0.22). Fall in the HPV-16 E6 and E7 
expression by other shRNA constructs in SiHa cells 
was also significant (Fig.  2b; p  <  0.05). Similar trend 
was observed in CaSki cells (Fig.  2c). No significant 
decrease was observed in HeLa cells (p  >  0.05; Addi-
tional file  4: Figure S4A) illustrating the specificity 
of the shRNA for HPV-16. Further, the potential to 
knockdown HPV-16 E6 and E7 expression by tissue 
specific NFκBEn–Pr+2-HPV-16–E6/E7 was compa-
rable to tissue non-specific CMVPr–HPV-16–E6/E7 
(p > 0.05). However, our NFκB–PLAP promoter, unlike 
CMV promoter, was active only under neoplastic con-
dition. The activity of NFκBEn–Pr+2-HPV-16–E6/E7 
was significantly higher than PLAPPr+2-HPV-16–E6/
E7 in both SiHa and CaSki cells (p < 0.05). Hence, we 
were able to increase the transcriptional activation of 
the downstream TGS inducing shRNA, while retain-
ing its tumour selective expression by fusing four cop-
ies of NFκB responsive element upstream to the PLAP 
promoter.
Reduction in expression of HPV‑16 E6 and E7 ameliorates 
p53 and abates E2FI targets
Reduction in the expression of HPV-16 E6 led to the 
activation of p53 as shown by increase in levels of p53 
target genes like Puma and Noxa (Fig.  2d–e). This was 
corroborated by p53 western blot (Fig.  2f–g). The 
degree of HPV-16 E6/E7 suppression corroborated with 
the restored levels of p53 and its target genes. Hence, 
increased expression of p53 and its target genes was 
as per the strength of shRNA expression constructs: 
NFκBEn–Pr+2-HPV-16–E6/E7  >  PLAPPr+2-HPV-16–
E6/E7. Likewise, down-regulation of E7 significantly 
decreased the expression of E2FI candidate genes like 
cyclin A2 and cyclin E in SiHa and CaSki cells (Fig. 2h, 
i; p < 0.05).
Suppression of HPV‑16 E6 and E7 reduced cell proliferation 
and triggered apoptosis
MTT assay revealed that there was concomitant decrease 
in cell proliferation of the test shRNA transfected SiHa 
and CaSki cells (Fig. 3a, b). Flow cytometric analysis by 
propidium iodide (PI) staining demonstrated increase in 
the percentage of cells in sub-G1 phase. This was in direct 
agreement with the potential of the construct express-
ing shRNA (Fig. 3c, d). As in the case of luciferase activ-
ity and HPV-16 E6/E7 down-regulation studies, greater 
degree of apoptosis and decreased cell proliferation was 
seen by NFκBEn–Pr+2-HPV-16–E6/E7 when compared 
with that by PLAPPr+2-HPV-16–E6/E7 (p  <  0.05). The 
results observed by NFκBEn–Pr+2-HPV-16–E6/E7 were 
also comparable to the tissue nonspecific CMVPr–HPV-
16–E6/E7 construct (p > 0.05).
Specificity of chimeric scFv‑F virosomes towards PLAP 
expressing cells
Real time fusion kinetics by fluorescence dequenching 
assay showed that the chimeric scFv-F virosomes spe-
cifically fused with PLAP positive cell lines (HeLa, CaSki 
and SiHa) but not with non PLAP cell line CHO which 
does not express PLAP. Inactivated chimeric virosomes 
(HC: Heat control), displayed negligible fusion with HeLa 
cells (Fig. 4a). The difference in the fusion observed might 
be dependent upon the number of PLAP molecules 
expressed by various cell types. Luciferase expression 
constructs (NFκBEn–Pr+24-luc; PLAPPr+24-luc and 
SV40-luc) packaged and delivered by chimeric scFv-F 
virosomes showed significant activity only in PLAP posi-
tive cells (Additional file 5: Figure S5A). It differed from 
lipofectamine based transfections as tissue non-specific 
SV40-luc did not elicit appreciable activity in non-PLAP 
cells (Fig. 1d, e). Time dependent fall in HPV-16 E6 and 
E7 levels, post chimeric virosomal delivery, in SiHa cells 
(Fig. 4b) were comparable to that by conventional meth-
ods (Fig. 2a). Significant fall in the expression of HPV-16 
E6 and E7 mRNA was seen both in SiHa and CaSki cells 
(p  <  0.05 for both; Fig.  4c, d). TGS was not effective in 
HeLa cells due to specificity of shRNA towards HPV-16 
(Additional file 6: Figure S6A)
HPV‑16 E6 and E7 inactivation post virosomal delivery 
affected p53 and E2F1 candidate genes
TGS inducing constructs, following chimeric viroso-
mal delivery, reduced the expression of HPV-16 E6 and 
restored the expression of p53 target genes like PUMA 
and NOXA (Fig. 4e, f ). This was corroborated by p53 pro-
tein status (Fig. 4g). Similarly, E7 suppression was accom-
panied by decrease in the expression of E2FI candidate 
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Fig. 2 Specificity of test shRNA towards HPV-16 enhancer. a Time dependent fall in the expression of HPV-16 E6 and E7 by NFκBEn–Pr+2-HPV-16–
E6/E7, in SiHa cells, showed maximum suppression after 5 days (p < 0.05 at all-time points). The apparent increase in E6 and E7 mRNA on the 6th 
day compared with 5th day was statistically insignificant (p = 0.22). b, c Decrease in E6 and E7 mRNA levels is seen in both HPV-16 positive cell lines 
SiHa and CaSki and the fall in E6/E7 expression is in concordance with strength of the construct driving shRNA expression. NFκBEn–Pr+2-HPV-16–
E6/E7 significantly decreased HPV-16 E6/E7 mRNA levels over PLAPPr+2-HPV-16–E6/E7 in SiHa cell line (p = 0.022 and p = 0.030 for E6 and E7, 
respectively) and CaSki (p = 0.041 and p = 0.017 for E6 and E7, respectively). d, e Post HPV-16 E6/E7 suppression by shRNA, significant increase in 
the expression of p53 target genes was observed in SiHa and CaSki cells at the mRNA level. f and g Restoration of p53 protein, post HPV-16 E6/E7 
suppression corroborated with the mRNA levels of PUMA and NOXA. h and i Decrease in the HPV-16 E7 expression, post shRNA treatment, signifi-
cantly reduced levels of E2FI candidate genes like cyclin A2 and E (p < 0.05).
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150ng 300ng 450ng 600ng 750ng 900ng 1050ng 1200ng
Fig. 3 HPV-16 E6/E7 suppression reduced cell proliferation and increased apoptosis. a and b SiHa and CaSki cells were transfected with various 
PLAP promoter/enhancer driven test/control shRNAs in different doses and percent cell proliferation was evaluated by MTT assay on the 6th day. 
Decrease in cell proliferation was dependent on the dose and strength of the shRNA construct (p < 0.05). Also, NFκBEn–Pr+2-HPV-16–E6/E7, when 
compared to PLAPPr+2-HPV-16–E6/E7, significantly reduced cell proliferation of both SiHa and CaSki to a greater degree (p = 0.042 and p = 0.029, 
respectively). c and d Flow cytometry was used to evaluate apoptosis (subG1). Increase in apoptosis was concordant with the strength of promoter/
enhancer construct and corroborated with the cell proliferation studies.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 Kinetics of chimeric scFv-F-virosome fusion and knockdown effects post virosomal delivery. a Fusion of R18 labelled chimeric Sendai F-viro-
somes was determined by fluorescence dequenching assay; significant fusion was observed only in PLAP positive cells but not in non-PLAP CHO 
cells. scFv virosomes with inactivated F-protein (HC: heat control) displayed poor fusion with HeLa cells confirming fusion specificity via scFv. b Time 
dependant fall in expression of HPV-16 E6/E7 by NFκBEn–Pr+2-HPV-16–E6/E7, post chimeric virosomal delivery, was comparable with conventional 
transfection results. c–f Decrease in the expression of HPV-16 E6/E7 and increase in the expression of p53 target genes was observed in both SiHa 
and CaSki cells and it was in accordance with strength of the shRNA construct. g Amelioration in p53 in SiHa and CaSki, at the protein level, fol-
lowed the same trend. h and i Post scFv F-virosomal delivery of the shRNA constructs, significant decrease in the expression of E2FI candidate genes 
(cyclin A2 and E) was observed in SiHa and CaSki cell lines (p < 0.05).
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genes cyclin A2 and cyclin E in SiHa and CaSki cells but 
not in HeLa cells (Fig. 4h, i)
TGS of HPV‑16 E6 and E7 increased caspase 3/7 activity
Significant increase in caspase 3/7 activity was observed 
in SiHa and CaSki cells five days post virosomal deliv-
ery of NFκBEn+2-HPV-16–E6/E7. However, no such 
increase was seen in HeLa and CHO cells (Fig. 5a).
HPV‑16 shRNA induced heterochromatization 
without affecting CpG methylation
Using ChIP assay, the levels of repressive epigenetic 
marks, like H3K9me2 and H3K27me3, were found 
enriched, around the target region, in test shRNA treated 
SiHa cells. Furthermore, treatment with histone dea-
cetylase (HDAC) inhibitor TSA reduced this enrich-
ment indicating that HDACs are primarily involved 
in the process (Fig.  5b). The methylation status of CpG 
islands showed no change between test or control shRNA 
treated cells (Fig. 5c, d). This indicates that the decrease 
in the expression of HPV-16 E6 and E7, by shRNA treat-
ment, is not due to DNA methylation.
shRNA decreases the transcription of enhancer associated 
transcripts
The levels of the enhancer associated transcripts 
decreased significantly in both SiHa and CaSki after 
virosomal delivery of entrapped test shRNA, supporting 
the previously proposed RNA:RNA model of TGS [27] 
(Fig. 5e).
Discussion
A tumour cell differs from a normal cell in two impor-
tant characteristics—the expression of neo-antigens [28] 
and the transcriptional re-activation of genes that were 
expressed in fetal life [29]. In a way both are manifesta-
tions of the same phenomenon—the aberrant transcrip-
tional activation of genes after neoplastic transformation 
results in the expression of proteins which then serve as 
neo-antigens. In this work we have combined both the 
processes for the targeting of a potentially tumour sup-
pressive shRNA to the affected cells. The shRNA used 
suppresses E6/E7 genes of HPV-16 and is a potential 
gene therapy modality for HPV-16 mediated cervical 
cancer. This in itself has an element of specificity because 
HPV-16 is integrated only in cancer cells. However, a fur-
ther degree of specificity was attempted by combining 
PLAP specific antigen mediated delivery with neopla-
sia specific PLAP promoter action. PLAP is also called 
germ cell alkaline phosphate (GCAP) [30]. The recom-
binant scFv antibody generated by us against PAP [24] 
also binds PLAP, which is antigenically similar and also 
expressed in an onco-developmental manner, but not 
with the other isozymes of AP. Its incorporation in the 
Sendai virus envelope provided specificity in delivery to 
the PLAP expressing transformed cells. A unique feature 
of this system is antibody targeted cytosolic delivery [24]. 
This feature enables the cargo to be delivered directly to 
the cytoplasm, thus bypassing endosomal uptake—a fea-
ture of the Sendai virosome envelope. Direct cytoplasmic 
uptake is expected to reduce degradation of the deliv-
ered cargo. The PLAP promoter, however, is distinct and 
the defined region [14] that provides specificity to gene 
expression was cloned and used either by itself or in tan-
dem with the NFκB enhancer. As the results indicate, 
the objectives of specificity and effective gene expres-
sion were achieved by this strategy. The PLAP promoter 
has not been used so far to drive the tumour cell specific 
expression of potential gene therapy candidates. Hence, 
we attempted to suppress expression of HPV-16 onco-
genes E6 and E7 via TGS induced by the PLAP promoter/
enhancer driven shRNA constructs.
When measuring luciferase activity, by Dual Luciferase 
Assay (Fig.  1), the activity of combined NFκB enhancer 
and PLAP promoter (NFκBEn–Pr+24-luc) was greater 
than that of PLAP promoter alone (PLAPPr+24-luc; 
p  <  0.05) in both SiHa and CaSki. However, it retained 
specificity for PLAP expressing cell lines. The activity of 
NFκBEn–Pr+24-luc was also comparable to the posi-
tive control SV40-luc (p  >  0.05). But, significant SV40 
mediated luciferase expression (p  <  0.05) was observed 
even in HepG2 and CHO cells, unlike PLAP specific 
NFκBEn–Pr+24-luc as the SV40 promoter is ubiqui-
tously expressed in all the cells. The above features of the 
naked constructs were retained after virosomal delivery.
The maintenance of the malignant aspect and behav-
iour of HPV transformed cervical cancer cells is depend-
ent on the expression of viral onco-proteins E6 and E7 
[16, 17]. Previously, we had used siRNA for heterochro-
matization of the HPV 16 LCR [31]. In this study, the 
specially designed PLAP promoter/enhancer driven 
shRNA targeting NF-1 binding site of HPV-16 LCR, 
reduced E6 and E7 expression only in SiHa and CaSki 
but not in HPV-18 integrated HeLa cell line demonstrat-
ing its specificity for HPV-16. The suppression of HPV-
16 E6 and E7 oncogene expression was in concordance 
with the strength of each construct (Fig. 2b, c; Additional 
file 4: S3A). The suppression of HPV-16 E6 and E7 by tis-
sue specific NFκBEn–Pr+2-HPV-16–E6/E7 was greater 
than PLAPPr+2-HPV-16–E6/E7 (p < 05; Fig. 2b, c) and 
was comparable to that achieved by tissue non-specific 
CMVPr–HPV-16–E6/E7 (p > 0.05) as the CMV promoter 
is tissue non-specific in nature.
The decrease in the expression of HPV-16 E6 and E7 
abrogated the malignant characteristics of SiHa and 
CaSki but not of HPV-18 integrated HeLa cell line. This 
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Fig. 5 Caspase activity and mechanism involved in TGS. a HPV-16 E6/E7 suppression by NFκBEn–Pr+2-HPV-16–E6/E7, 5 days post virosomal deliv-
ery, led to increase in the caspase 3/7 activity in SiHa (p < 0.005) and CaSki (p = 0.02) cell lines. No such increase was observed in HeLa (p = 0.38) 
and CHO cells (p = 0.41). b Chip assay in SiHa cells transfected with NFκBEn–Pr+2 HPV-16–E6/E7 showed the silencing of the target region as a 
result of heterochromatization by methylation of histone tails (H3K9Me2 and H3K27Me3; p < 0.001 for both). However, cells pre-treated with TSA, 
did not show significant enrichment indicating that in the presence of TSA, shRNA failed to induce significant heterochromatization (p > 0.05). c 
and d No difference in the methylation pattern of the CpG islands, around the target LCR region, of SiHa cell line was observed by bisulphite PCR 
and followed by DNA sequencing. e The levels of enhancer associated transcripts decreased significantly post chimeric scFv-F virosomal delivery of 
NFκBEn–Pr+2 HPV-16–E6/E7 construct in both HPV-16 integrated SiHa and CaSki cells (p < 0.05).
Page 12 of 14Khan et al. J Transl Med  (2015) 13:254 
was evident by restoration in expression signatures of 
p53 and its target genes like Puma and Noxa and reduc-
tion in the expression profile of pRB candidate genes like 
cyclin A2 and cyclin E. The extent of reduction/restora-
tion of these genes was in consonance with the strength 
of the promoter/enhancer driving shRNA expression 
(Fig. 2d, e; Additional file 4: Figure 3a, b). HPV-16 E6 and 
E7 suppressed cells showed decreased cell proliferation 
and increased apoptosis by MTT assay and flow cyto-
metric analysis, respectively (Fig.  3a–d). In the cell pro-
liferation and apoptosis studies, a greater decrease in the 
cell proliferation and increase in apoptosis was seen by 
NFκB–PLAP promoter driven shRNA (NFκBEn–Pr+2-
HPV-16–E6/E7) when compared with that of the PLAP 
promoter alone (PLAPPr+2-HPV-16–E6/E7; p < 0.05).
TGS has the potential to cause long-term gene silencing 
by mechanisms such as heterochromatization, DNA meth-
ylation or interference with the RNA polymerase binding 
[25, 27, 32–35]. In our study, shRNA mediated TGS was 
associated with epigenetic modifications, i.e., H3K9Me2 
and H3K27Me3 around the target region. The enrichment 
around these histones (H3K9Me2 and H3K27Me3) was 
reduced by TSA treatment indicating a likely involvement 
of HDACs (Fig. 5b). However, we observed no CpG DNA 
methylation suggesting that the down-regulation of HPV-
16 E6/E7 occurs due to heterochromatization only (Fig. 5c). 
shRNA possibly acted by interacting with the enhancer 
associated transcripts, since significant fall in the level of 
these transcripts was observed post shRNA treatment 
(Fig.  5e). Essentially, the mechanism by which TGS was 
induced by current constructs was similar to what we have 
demonstrated earlier by siRNA [31].
The combination of antibody based targeted particu-
late delivery with tumour specific promoter activation 
has not been reported earlier. We also report for the first 
time the use of a region of the PLAP promoter, in tandem 
with the NFκB enhancer, for driving gene expression in 
a manner that is both specific and highly efficient in the 
range that can be achieved by the viral CMV promoter. 
This has been shown for various parameters that include 
the luciferase assay, ability to reduce HPV-16 E6/E7 tran-
script levels, reduction in cell proliferation and increase 
in apoptotic subG1 fraction. With this, we have been able 
to demonstrate TGS of E6 and E7 genes in HPV-16 trans-
formed cervical carcinoma cells, leading to extensive cell 
death. This approach could also be utilised for the expres-
sion of beneficial genetic sequences in cancer/germ cells 
which ectopically or otherwise express PLAP. This com-
bined cell delivery/transformation specific gene expres-
sion system, could serve as a paradigm for therapeutic 
gene delivery in malignantly transformed cells.
Conclusions
The PLAP promoter and NFκB enhancer driven TGS 
inducing system, in association with the scFv directed 
Sendai virosome, offers a novel mode of targeting cervi-
cal cancer cells. This system could help to achieve dual 
cancer cell specificity firstly at the level of delivery and 
secondly by cancer dependent expression of the payload. 
This system may also be utilized in conjunction with 
other putative gene therapy approaches such as gene 
dependent enzyme prodrug therapy (GDEPT).
Additional files
Additional file 1. Generation of various PLAP promoter/enhancer medi-
ated constructs.
Additional file 2. Sequence of the primers used in the study.
Additional file 3: The extent of chimeric scFv-virosome fusion 
assessed by Fluorescence Dequencing. The fluorophore octadecyl 
rhodamine beta chloride (R18) which has intrinsic quenching properties 
at close proximity (high concentration) was incorporated in the mem-
brane of the virosome. When fusion with the cell occurs, the membrane 
fuse and mixing of target cell membrane’s and virosomal lipids takes 
place. This increases the distance between R18 molecules and leads to the 
dequenching and the fluorescence (490 excitation and 520 nm emission) 
is recorded with a spectrofluorimeter.
Additional file 4: Figure S4. Specificity of E6/E7 shRNA towards HPV-16 
enhancer HPV-18 integrated cell line (HeLa) was transfected with various 
TGS inducing constructs (NFκBEn–Pr+2-HPV-16–E6/E7, PLAPPr+2-
HPV-16–E6/E7 and CMVPr–HPV-16–E6/E7) along with their scrambled 
controls and the fall in expression was evaluated by real time PCR after 
normalization with three housekeeping genes (18s, GAPDH and β-actin). 
A) No, significant fall in expression of E6 and E7 mRNA was observed in 
HeLa, with any shRNA construct demonstrating their specificity for HPV-16 
enhancer. B) There was no increase in the expression of p53 target genes 
like PUMA & NOXA in HeLa. C) Decrease in expression of E2FI target genes 
like cyclin A2 and cyclin E was not significant in HeLa.
Additional file 5: Figure S5. The transcriptional activity and specific-
ity of various luciferase constructs. (A) PLAP positive HPV-18 integrated 
cervical cancer cell line (HeLa). (B) HPV-16 integrated cell line (SiHa). 
(C) HPV-18 and HPV-16 integrated cell line (CaSki). (D) PLAP negative 
hepatoma cell lines (HepG2). (E) Non- PLAP non-human cell line (CHO) 
were co-transfected by chimeric virosomes (C-scFv-V) separately in trip-
licates with luciferase expression vectors (PLAPPr+24–luc, SV40-luc and 
NFκBEn-Pr+24–luc) and Renilla expression vector (pRL-TK). The luciferase 
activity of each transfection was normalised by the Renilla reading. The 
luciferase activity is represented by the ratio of specific promoter over 
the activity of PGL3-Basic. No luciferase activity was observed in PLAP 
negative cell lines HepG2 and CHO (D and E) even by tissue nonspecific 
construct SV40-luc demonstrating specific delivery of packaged cargo 
only to PLAP expressing cells.
Additional file 6: Figure S6. Knockdown effects in HeLa post Immuno-
virosomal delivery. Various shRNA constructs (NFκBEn–Pr+2-HPV-16–E6/
E7, PLAPPr+2-HPV-16–E6/E7 and CMVPr–HPV-16–E6/E7) and their 
controls were packaged and delivered by chimeric virosomes to HeLa. (A) 
There was no significant decrease in E6 and E7 oncogene expression with 
any shRNA expression construct. (B) PUMA and NOXA -p53 target genes 
were not restored in HeLa. (C) E2F1 candidate genes were not affected 
post virosomal delivery of shRNA constructs in HeLa, demonstrating 
specificity of shRNA for HPV-16 LCR.
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